Opdivo and Hyperkalemia - a phase IV clinical study of FDA data

Summary:

Hyperkalemia is reported as a side effect among people who take Opdivo (nivolumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Yervoy, and have Metastatic renal cell carcinoma.

The phase IV clinical study analyzes which people have Hyperkalemia when taking Opdivo. It is created by eHealthMe based on reports of 56,294 people who have side effects when taking Opdivo from the FDA, and is updated regularly.

What is Opdivo?

Opdivo has active ingredients of nivolumab. eHealthMe is studying from 56,331 Opdivo users. Check the latest studies of Opdivo.

What is Hyperkalemia?

Hyperkalemia (damage to or disease of the kidney) is found to be associated with 1,957 drugs and 2,936 conditions by eHealthMe. Check the latest studies of Hyperkalemia.

On Apr, 18, 2026

56,294 people reported to have side effects when taking Opdivo.
Among them, 172 people (0.31%) have Hyperkalemia.

Among these 172 people:

* Approximation only. Some reports may have incomplete information.

Do you take Opdivo and have Hyperkalemia?

- Check whether Hyperkalemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Opdivo:

Opdivo (56,331 reports)

Hyperkalemia treatments and more:

Hyperkalemia (78,084 reports)

How severe was Hyperkalemia and when was it recovered:

Hyperkalemia in Opdivo

Expand to all the drugs that have ingredients of nivolumab:

Hyperkalemia and drugs with ingredients of nivolumab (501 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Opdivo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperkalemia:

Hyperkalemia (1,957 drugs)

Browse all the conditions that are associated with Hyperkalemia:

Hyperkalemia (2,936 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nivolumab (the active ingredients of Opdivo) and Opdivo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.